Cetuximab in small bowel adenocarcinoma: a new friend?
Santini
D
D
Fratto
M E
ME
Spoto
C
C
Russo
A
A
Galluzzo
S
S
Zoccoli
A
A
Vincenzi
B
B
Tonini
G
G
D000230:Adenocarcinoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D000068818:Cetuximab; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007167:Immunotherapy; D007414:Intestinal Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D007421:Intestine, Small / Q000473:pathology; D000077146:Irinotecan; D008297:Male; D008875:Middle Aged; D013534:Survival
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000077146:Irinotecan; D000068818:Cetuximab; D002166:Camptothecin